Lexaria Bioscience Corp. (NASDAQ: LEXX) Developing Powerful Tech to Treat Hypertension
August 09 2022 - 8:30AM
via InvestorWire —
Lexaria Bioscience Corp. (NASDAQ:
LEXX) today announces its placement in an editorial
published by NetworkNewsWire ("NNW"), one of 50+ trusted brands
within the InvestorBrandNetwork (“IBN”), a multifaceted financial
news and publishing company for private and public entities.
To view the full publication, “The Power of Science to Stop a
Killer,” please visit: https://nnw.fm/9kD5b
Nearly half of all American adults suffer from hypertension
(high blood pressure), often referred to as a silent killer. More
than 114 million adults in this country are at risk from damage
caused by the long-term force of blood beating against artery
walls, which often leads to disease and death. The good news is
that hypertension is treatable and manageable through lifestyle
changes and medications. Fact is, there are several approved blood
pressure medications on the market, yet only about one in five
people diagnosed with hypertension take medication. Why so few?
Unfortunately, the side effects of these medications often outweigh
the benefits.
However, a new hypertension blockbuster may be imminent. A
safer, better-tolerated drug candidate just marked a major
milestone on the path to approval and commercialization. A global
innovator in drug-delivery platforms, Lexaria Bioscience
Corp. (NASDAQ: LEXX) has been quietly progressing through
clinical processes and amassing a growing body of evidence that
strongly supports use of its patented DehydraTECH(TM) technology in
hypertension therapeutics.
About Lexaria Bioscience Corp.
Lexaria’s patented drug delivery technology, DehydraTECH(TM),
improves the way active pharmaceutical ingredients (“APIs”) enter
the bloodstream by promoting more effective oral delivery. Since
2016, DehydraTECH has repeatedly demonstrated the ability to
increase bioabsorption with cannabinoids and nicotine by up to five
to ten times, reduce time of onset from one to two hours to
minutes, and mask unwanted tastes; the innovative tech is also
being evaluated for orally administered anti-viral drugs,
nonsteroidal anti-inflammatory drugs (“NSAIDs”), PDE5 inhibitors
and more. DehydraTECH has also evidenced an ability to deliver some
drugs more effectively across the blood brain barrier. Lexaria
operates a licensed in-house research laboratory and holds a robust
intellectual property portfolio with 25 patents granted and more
than 50 patents pending worldwide.
For more information about the company, visit
at www.LexariaBioscience.com.
NOTE TO INVESTORS: The latest news and
updates relating to LEXX are available in the company’s newsroom
at https://ibn.fm/LEXX
About NetworkNewsWire
NetworkNewsWire (NNW) is an information service that provides
(1) access to our news aggregation and syndication servers,
(2) NetworkNewsBreaks that summarize corporate news and
information, (3) enhanced press release services, (4) social media
distribution and optimization services, and (5) a full array of
corporate communication solutions. As a multifaceted financial news
and content distribution company with an extensive team of
contributing journalists and writers, NNW is uniquely positioned to
best serve private and public companies that desire to reach a wide
audience of investors, consumers, journalists and the general
public. NNW has an ever-growing distribution network of more than
5,000 key syndication outlets across the country. By cutting
through the overload of information in today’s market, NNW brings
its clients unparalleled visibility, recognition and brand
awareness.
NNW is where news, content and information converge.
To receive SMS text alerts from NetworkNewsWire, text “STOCKS”
to 77948 (U.S. Mobile Phones Only)For more information please
visit https://www.NetworkNewsWire.com
Please see full terms of use and disclaimers on the
NetworkNewsWire website applicable to all content provided by NNW,
wherever published or
re-published: http://NNW.fm/Disclaimer
NetworkNewsWire (NNW) New York, New York www.NetworkNewsWire.com
212.418.1217 Office Editor@NetworkNewsWire.com
NetworkNewsWire is part of the InvestorBrandNetwork
Lexaria Bioscience (NASDAQ:LEXX)
Historical Stock Chart
From Mar 2024 to Apr 2024
Lexaria Bioscience (NASDAQ:LEXX)
Historical Stock Chart
From Apr 2023 to Apr 2024